Zogenix Announces Proposed Public Offering of 4,300,000 Shares of Common Stock
02 oct. 2017 06h52 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
29 sept. 2017 07h00 HE
|
Zogenix, Inc.
Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in...
Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results
08 août 2017 16h01 HE
|
Zogenix, Inc.
Top-Line Results of First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Expected in Third Quarter 2017 Second Phase 3 Clinical Trial in Dravet Syndrome, Study 1504, Enrolling According to Plan ...
Zogenix to Release Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8
01 août 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Receives Orphan Drug Designation from FDA for ZX008 in Treatment of Lennox Gastaut Syndrome
22 juin 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., June 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Present at the Jefferies 2017 Global Healthcare Conference
31 mai 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., May 31, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Announces Presentation of ZX008 Mechanism of Action Data at Annual Meeting of Society of Biological Psychiatry
22 mai 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., May 22, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix Provides Corporate Update and Reports First Quarter 2017 Financial Results
04 mai 2017 16h01 HE
|
Zogenix, Inc.
Completed Enrollment of Study 1, First Phase 3 Clinical Trial of ZX008 in Dravet Syndrome; Top-Line Results Expected in Third Quarter 2017 IND Accepted by FDA for Phase 3 Clinical Trial of...
Zogenix Completes Enrollment in First ZX008 Phase 3 Clinical Trial in Dravet Syndrome
27 avr. 2017 08h01 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...
Zogenix to Release First Quarter 2017 Financial Results and Host Conference Call and Webcast on May 4
27 avr. 2017 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS)...